These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 22215854)
1. StatBite: Drugs in development by therapeutic area (2010). J Natl Cancer Inst; 2012 Jan; 104(2):86. PubMed ID: 22215854 [No Abstract] [Full Text] [Related]
2. Discontinued drugs in 2008: oncology drugs. Williams R Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760 [TBL] [Abstract][Full Text] [Related]
3. Oncology drug development: what is changing? Yancey MA Clin J Oncol Nurs; 2008 Oct; 12(5):713-5. PubMed ID: 18842527 [No Abstract] [Full Text] [Related]
4. The role of the National Cancer Institute in drug development. Doroshow J Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997 [No Abstract] [Full Text] [Related]
5. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Park JW; Kerbel RS; Kelloff GJ; Barrett JC; Chabner BA; Parkinson DR; Peck J; Ruddon RW; Sigman CC; Slamon DJ Clin Cancer Res; 2004 Jun; 10(11):3885-96. PubMed ID: 15173098 [No Abstract] [Full Text] [Related]
6. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854 [TBL] [Abstract][Full Text] [Related]
7. The convergence of cancer prevention and therapy in early-phase clinical drug development. Abbruzzese JL; Lippman SM Cancer Cell; 2004 Oct; 6(4):321-6. PubMed ID: 15488755 [TBL] [Abstract][Full Text] [Related]
9. Strategy for the development of novel anticancer drugs. Saijo N; Tamura T; Nishio K Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152 [TBL] [Abstract][Full Text] [Related]
10. The contemporary drug development process: advances and challenges in preclinical and clinical development. Garrett MD; Walton MI; McDonald E; Judson I; Workman P Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708 [TBL] [Abstract][Full Text] [Related]
11. Ixabepilone and the narrow path to developing new cytotoxic drugs. Gianni L J Clin Oncol; 2007 Aug; 25(23):3389-91. PubMed ID: 17606970 [No Abstract] [Full Text] [Related]
12. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Sawyers CL Genes Dev; 2003 Dec; 17(24):2998-3010. PubMed ID: 14701871 [No Abstract] [Full Text] [Related]
14. Antibody-drug conjugates for cancer: poised to deliver? Hughes B Nat Rev Drug Discov; 2010 Sep; 9(9):665-7. PubMed ID: 20811367 [No Abstract] [Full Text] [Related]
15. SRC as a potential therapeutic target in solid tumor oncology. Gallick GE Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218 [No Abstract] [Full Text] [Related]
16. Developing drugs that do not cause tumor regression. Stadler W Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462 [No Abstract] [Full Text] [Related]
17. [Development for and clinical trials of molecular targeting drugs]. Takashima A; Fukuda H; Shibata T Gan To Kagaku Ryoho; 2010 May; 37(5):822-7. PubMed ID: 20524257 [No Abstract] [Full Text] [Related]
18. Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. Fine BM; Amler L Clin Pharmacol Ther; 2009 May; 85(5):535-8. PubMed ID: 19295504 [No Abstract] [Full Text] [Related]
20. Advances and challenges in the use of biomarkers in clinical trials. Chabner B Clin Adv Hematol Oncol; 2008 Jan; 6(1):42-3. PubMed ID: 18322440 [No Abstract] [Full Text] [Related] [Next] [New Search]